Clinical Trial Goal
To find out:
- The highest dose of rezatapopt that's safe to give with azacitidine
- If rezatapopt is safe and works well to treat TP53Y220C+ AML or MDS that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have AML or MDS that has relapsed or is refractory
- Have cancer cells with TP53Y220C mutation (TP53Y220C+). Your doctor can tell you this
- Do not have acute promyelocytic leukemia
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Azacitidine is a drug that blocks the growth of cancer cells.
Rezatapopt is a small molecule reactivator that binds to P53Y220C.
You’ll get:
Rezatapopt is a small molecule reactivator that binds to P53Y220C.
You’ll get:
- Azacitidine – Given as intravenous (IV) infusions for 1 week
- Rezatapopt – A pill that you take by mouth 1 time each day
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for about 1 year.
The Food and Drug Administration (FDA) has approved azacitidine to treat AML and MDS. The FDA has not yet approved rezatapopt.
Locations
The University of Texas MD Anderson Cancer CenterRECRUITING
Houston, Texas
Courtney DiNardo, MD, 713-794-1141, cdinardo@mdanderson.org
Sponsors
collaborator: Memorial Sloan Kettering Cancer Center (MSK), collaborator: PMV Pharmaceuticals, Inc, lead: M.D. Anderson Cancer Center
